Form 4: Sonoma Pharmaceuticals Director Acquires Stock Options
SEC Form 4 Filing
Philippe Weigerstorfer, a director of Sonoma Pharmaceuticals, acquired 7,500 stock options on January 2, 2025, as part of the company's annual grant for board services.
Summary
- Philippe Weigerstorfer, a director at Sonoma Pharmaceuticals, acquired 7,500 stock options on January 2, 2025.
- The options have an exercise price of $2.68.
- The options vest in three equal installments on January 2, 2026, January 2, 2027, and January 2, 2028, or upon a change of control.
- Following the transaction, Mr. Weigerstorfer beneficially owns 10,001 derivative securities.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. It reflects a routine grant of stock options to a director, which is generally viewed as a positive sign of aligning interests between management and shareholders.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Management Comments
- The options were awarded and granted to Mr. Weigerstorfer for services performed on the Board of Directors as part of the Company's annual grant of stock options.
Industry Context
Stock option grants to directors are a common practice in publicly traded companies as a form of compensation and incentive alignment.
Comparison to Industry Standards
- Stock option grants to board members are a typical component of compensation packages in the pharmaceutical industry.
- The vesting schedule of one-third each year for three years is a standard vesting arrangement.
- Comparing the size of the grant to similar companies would require further analysis of Sonoma Pharmaceuticals' compensation policies and peer group data.
Stakeholder Impact
- The stock option grant aligns the director's interests with those of the shareholders, potentially encouraging decisions that increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 01/02/2025 | Date of the transaction: Director acquired 7,500 stock options. |
| 01/02/2025 | Date of grant of stock options. |
| 01/02/2026 | First vesting date for one-third of the options. |
| 01/02/2027 | Second vesting date for one-third of the options. |
| 01/02/2028 | Third vesting date for one-third of the options. |
| 01/02/2035 | Expiration date of the stock options. |
| 01/03/2025 | Date of signature for the Form 4 filing. |
Keywords
stock options, Form 4, director, Sonoma Pharmaceuticals, SNOA, beneficial ownership, securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.